NCT06069726View on ClinicalTrials.gov

A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 21, 2024

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2027

Conditions
Recurrent Glioblastoma
Interventions
DRUG

Atezolizumab

One dose of atezolizumab will be given prior to resection.

Trial Locations (4)

27705

RECRUITING

Duke University, Durham

64111

RECRUITING

Saint Luke's Cancer Institute, Kansas City

84112

RECRUITING

Huntsman Cancer Institute, Salt Lake City

94143

RECRUITING

University of California, San Francisco, San Francisco

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
lead

Duke University

OTHER

NCT06069726 - A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial | Biotech Hunter | Biotech Hunter